The following is compiled from public reporting, with sources and dates noted, for information only and not as medical advice. A technology being "approved / performed" does not mean it suits every patient; suitability must be assessed by the hospital and its licensed physicians. For specific availability, cost and indications, please refer to the latest announcements from hospitals and authorities.
2026-11-09Innovative Drugs
US Patients Travel to China for Medicine: The Cross-Border Journey of a Chinese-Developed Drug
Sunvozertinib, a targeted lung-cancer drug developed by Chinese company Dizal Pharmaceutical, was approved in China in August 2023 and by the US FDA in July 2025 — but was not yet commercially available in the US. American patients obtained the medicine through relatives in China, with some flying to Shanghai to bring it home; the story drew over 2 million reads on social media. The drug officially launched in the US on 23 October 2026.
For international patients: China is becoming an earlier-access market for some original innovative drugs. Cross-border medicine purchase involves regulatory, cold-chain and medication-safety issues — always consult a qualified physician and use legitimate channels; never self-source drugs abroad.
Source: Xinhua News Agency ↗2026-11-04Surgical Robotics
Domestic Single-Port Robot Completes World's First Remote Transanal Radical Rectal Cancer Surgery
A team at Daping Hospital of Army Medical University completed two remote single-port robot-assisted radical rectal cancer surgeries over distances of more than a thousand kilometers. The transanal minimally invasive approach is reported, via literature review, to be the world's first of its kind. The domestic single-port robot integrates high-definition 3D endoscopy and multi-degree-of-freedom snake-like robotic arms into a single channel, entering through the natural transanal route to remove the tumor while maximally preserving anal function.
For overseas patients: It shows China has mature experience in minimally invasive, function-preserving surgery for very low rectal cancer, and remote surgery opens up cross-regional expert collaboration for complex cases.
Source: Science and Technology Daily ↗2026-11-03Cell Therapy
China's First In-Vivo mRNA CAR-T Therapy Approved for Clinical Trials
Ruibondi's dual-target in-vivo CAR-T product RGL-208, part of Hengrui Medicine, received implicit approval from the National Medical Products Administration for clinical trials, for relapsed or refractory B-cell non-Hodgkin lymphoma. It is China's first LNP-mRNA in-vivo CAR-T therapy to gain clinical approval. Unlike conventional ex-vivo manufacturing, it generates CAR-T cells directly inside the body, eliminating apheresis and ex-vivo preparation; reporting suggests it could significantly lower the cost per treatment course.
For overseas patients: If in-vivo CAR-T matures, it could shorten waiting times and reduce costs, a direction worth watching for lymphoma patients; it is still at the clinical stage and not yet a widely accessible standard treatment.
Source: The Paper ↗2026-10-31Remote Surgery
Sanya and Haikou Complete Complex Robotic Surgery "Across the Distance"
Sanya Central Hospital and Hainan Provincial Hospital of Traditional Chinese Medicine completed a remote laparoscopic robotic surgery in a two-way interactive mode, covering gynecology and urology. One case of ureteral reconstruction required over a hundred fine laparoscopic sutures for anastomosis, demanding extremely high precision.
For overseas patients: Remote robotic surgery has entered real clinical use in multiple regions of China, meaning high-quality surgical expertise can be dispatched across regions and access to complex minimally invasive surgery is expanding.
Source: Jintai Information ↗2026-08-18Innovative Drugs
38 "Globally New" Innovative Drugs Approved in the First Half, Including Several World-Firsts
According to the National Medical Products Administration, by the end of June a total of 2,318 drug marketing registration applications had been approved, including 38 "globally new" innovative drugs. All 11 drugs with new targets or new mechanisms approved in the first half of 2026 were independently developed, including China's first radioactive diagnostic drug, the world's first antibody-drug conjugate for nasopharyngeal carcinoma, and the world's first CAR-T drug for solid tumors.
For overseas patients: China is becoming the launch site for some world-first drugs, improving access to new therapies for Asian-prevalent cancers such as gastric and nasopharyngeal cancer; use requires specialist assessment of indications and access routes.
Source: CCTV ↗2026-06-22CAR-T
World's First CAR-T Product for Solid Tumors Approved in China
Carsgen's independently developed Claudin18.2 autologous humanized CAR-T product "Kailimei" (satcabtagene autoleucel injection) was approved by the National Medical Products Administration for Claudin18.2-positive, HER2-negative advanced gastric / gastroesophageal junction adenocarcinoma after at least two lines of therapy failure. It is the world's first CAR-T product approved for a solid tumor.
For overseas patients: Solid tumors account for over 90% of malignancies and have long lacked effective CAR-T options. As a China-first launch, it offers a new treatment choice for advanced gastric cancer patients who have failed standard therapy, subject to assessment by a specialist hospital.
Source: The Paper ↗2026-04Emergency Surgery
World's First Remote Emergency Surgery: Chengdu Expert Operates on Lhasa Patient with Ruptured Liver Cancer
According to reports, with support from a robotic remote surgery system, Gao Fengwei's team performed a right hepatectomy and tumor resection from a console in Chengdu for a patient in Lhasa, a thousand kilometers away, suffering from ruptured and bleeding liver cancer. Remote surgery in such emergencies was previously limited by the inability of experts to arrive in time.
For overseas patients: It reflects China's technical accumulation in remote surgery and critical-care management, and makes cross-regional expert collaboration a foreseeable medical resource.
Source: People's Daily ↗2026-03-28Brain-Computer Interface
World's First Invasive Brain-Computer Interface Medical Device Approved in China
The National Medical Products Administration approved the marketing of the "Implanted Brain-Computer Interface Hand Motor Function Compensation System" (NEO), developed by Hong Bo's team at Tsinghua University. Using minimally invasive epidural implantation and wireless power-and-data communication, it helps patients with cervical spinal cord injury and paraplegia achieve brain-controlled grasping. Before approval, 32 clinical implants had been completed at 11 hospitals nationwide, with all patients achieving brain-controlled grasping.
For overseas patients: This is a milestone taking brain-computer interfaces from the lab into clinical practice, bringing new rehabilitation possibilities to patients with spinal cord injury; indications are currently well defined and require assessment by qualified institutions.
Source: China Youth Daily ↗2026-03-29Brain-Computer Interface
Domestic "Beinao-1" Completes Multiple Human Implants, Entering a Fast Track to Application
According to Xinhua, academician Zhao Jizong of the Chinese Academy of Sciences introduced that "Beinao-1," the world's first high-throughput (over 100 channels) wireless semi-invasive brain-computer product, has completed 7 human implants with good recovery, achieving motor and speech function reconstruction; "Beinao-2" has entered clinical validation. Beijing Tiantan Hospital and Peking Union Medical College Hospital have opened brain-computer interface assessment clinics.
For overseas patients: China is at the forefront of clinical translation of brain-computer interfaces, and motor and speech reconstruction offers a new path for patients with neurological injuries, with dedicated assessment clinics easing access.
Source: Xinhua ↗2026-04Cancer Prevention
Domestic Laser Interstitial Thermal Therapy and Other New Technologies Used for Precise Brain Tumor Ablation
According to reports, China's independently developed laser interstitial thermal therapy can precisely ablate grain-sized lesions deep in brain tumors via a laser fiber probe. Data from the same period show China's overall cancer mortality rate declining year by year, with gastric and liver cancer mortality falling about 3.9% and 3.2% annually respectively; in 2025 the total value of overseas licensing deals for innovative drugs exceeded US$130 billion.
For overseas patients: Minimally invasive precise ablation and domestic innovative drugs are advancing together, offering an alternative for brain tumor patients unsuitable for open surgery, subject to assessment by neurosurgery and oncology specialists.
Source: Tencent News ↗